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JOURNAL OF HEPATOLOGYTo the Editor:
We are grateful for the opportunity to address the ﬁndings of two
recent studies on neuroinﬂammation and cognition in HCV
referred to in the letter above, and published subsequent to the
submission of our paper to this Journal.
The ﬁrst study of Weissenborn et al. examined differences in
cerebral metabolites and cognition in 53 HCV positive subjects
compared to 26 healthy controls [1]. Consistent with numerous
other studies on this topic in the literature, HCV positive patients
were more fatigued, more depressed and performed signiﬁcantly
worse in tests of attention, reaction time and working memory
than HCV negative controls. Moreover, higher levels of choline
(Cho) were shown in basal ganglia and white matter of HCV posi-
tive patients than in controls, indicative of a neuroinﬂamatory
effect of HCV.
Subsequent to our publication of improved cognition in addi-
tion to a reduction in cerebral metabolites following treatment-
induced viral clearance, Dr. Weissenborn re-analyzed her data.
The reader may recall that we reported signiﬁcant improvements
in the domains of verbal learning and memory in sustained viro-
logical responders (SVRs) but not in NR/Rs (non-responders/
relapsers). Moreover, we found signiﬁcant reductions in cho-
line/creatine (Cho/Cr) and myoinositol/creatine (MI/Cr) as mea-
sured from the basal ganglia of SVRs, which was not observed
in NR/Rs [2]. Weissenborn’s re-analysis included an additional
nine HCV PCR negative subjects, six SVRs, and 18 non-responders
(NRs) who were not part of the published study group, but who
had undergone the same study protocol. In this retrospective
analysis, SVRs performed better than NRs on psychometric test-
ing (especially on testing of verbal recall) but these differences
were not signiﬁcant. In the MRS component of their study, PCR
positive subjects demonstrated signiﬁcantly higher levels of
Cho, MI and Cr than PCR negative patients but these differences
were noted in the occipital cortex rather than the basal ganglia,
as in our study.
Several problems arise when comparisons are drawn between
two very different studies. Firstly, Dr. Weissenborn’s data comes
from a cross sectional study, comparing group means of subjects
that were matched for age only. Data analysis obtained from a
single point in time cannot be reliably compared to our longitu-
dinal study, where each subject was tested at multiple time
points and served as their own control. Secondly, as outlined by
Dr. Weissenborn, technical differences in voxel positioning and
data acquisition (metabolite quantiﬁcation) may account for
varying results. The voxel placed in the basal ganglia in our study
did indeed contain a section of internal capsule between the cau-
date and putamen, as have earlier studies of HCV patients [3]. The
placement of this voxel was carefully reproduced for each study
in the same patient. The presence of white matter in part of the
voxel should not introduce a systematic difference in metabolite
ratios over time and does not invalidate our ﬁndings of a treat-
ment effect on MRS ratios. In addition, we expressed each ofJournal of Hepatology 20the metabolites of interest as a ratio of the internal control crea-
tine, as have most investigators in this ﬁeld. While it may be
more advantageous to perform absolute quantiﬁcation of metab-
olite concentrations, two recent studies have shown that ratios to
creatine provide similar ﬁndings to absolute quantiﬁcation, even
in studies of cerebral inﬂammation [4,5].
It would be more accurate to compare our results to the recent
ﬁndings of Pattullo et al., whose longitudinal design had much in
common with our study protocol [6]. They reported minimal
changes in cognition and markers of cerebral inﬂammation in
31 SVRs when compared to nine NRs. Possible explanations for
differences between Pattullo’s study and ours are as follows.
Firstly, their psychometric testing occurred at two time points
12–18 months apart, as opposed to ours which had three testing
points over a shorter time frame (9–15 months). It is possible
that our results are partially reﬂective of practice effects and
not resolution of cognitive abnormalities. If this is the case, it is
still worth noting that SVRs were more likely to beneﬁt from
the effect of practice than NR/Rs. Secondly, due to stringent
exclusion criteria, HCV positive subjects in Pattullo’s study had
very healthy neurocognitive scores at baseline and it is therefore
not surprising that further improvements in cognition were not
observed in spite of viral clearance. This is in stark contrast to
our ﬁndings, whereby, in spite of excluding co-morbidities
known to affect cognition, 50–71% of the HCV study group had
impaired scores on verbal learning domains at baseline when
compared against normative means. Furthermore, while Pattullo
and colleagues did not ﬁnd any signiﬁcant differences in metab-
olite ratios measured from the basal ganglia (globus pallidus) in
SVRs when compared to NRs in this very comprehensive study,
they did however observe an increase in basal ganglia N-acetyl
aspartate (NAA) in SVRs over time, a ﬁnding that is in keeping
with the concept of improved neuronal integrity following viral
clearance.
In conclusion, we accept that our study numbers are small.
We have presented results of a pilot study that merit further
exploration in larger studies with a longer follow-up to assess
for ‘‘delayed’’ beneﬁts of HCV eradication, or studies employing
the techniques of functional MRI allowing direct observation of
brain function, before and after anti-viral therapy.12 vol. 57 j 921–934 923
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Why 88% of US military veterans with HCV are not treated
Legislation should be passed allowing veterans with HCV to
qualify for their choice of Medicaid or Medicare so that they
obtain antiviral therapy in the private sector. Since Dr. Kizer
no longer in charge of the VA, it is very clear that the VA is not
ing to treat very many of them.
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Letters to the EditorTo the Editor:
The article in the February issue of the Journal of Hepatology
reported that less than 12% of American military veterans identi-
ﬁed with HCV were treated with antiviral therapy [1]. The Veter-
ans Administration does not want to spend adequate funds to
cure patients with hepatitis C. Dr. Kenneth Kizer, Under Secretary
for Health in the US Department of Veterans Affairs (VA), gave
HCV a high priority but unfortunately he left the VA in 1999. Sub-
sequent leadership has not shown enthusiasm for treating HCV.
The Director of Pharmacy and the Chief of Staff at my local VA
hospital told me that I spent too much money treating HCV. Boce-
previr and telaprevir are both on the hospital formulary but tela-
previr prescriptions are routinely denied because it is more
expensive. Patients must jump multiple hurdles before qualifying
for antiviral therapy. No one would refuse to give coronary artery
stents or bypass grafts to a veteran who smokes but veterans who
do not completely abstain from alcohol for three months are
refused antiviral therapy. In spite of difﬁculties, 585 of 1372
(43%) HCV RNA positive patients received antiviral therapy
between 1998 and 2010 at our local VA hospital; 226 of 583 trea-
ted (39%) achieved SVR [2]. 36% of deaths were from HCC or liver
failure. Veterans with sustained viral response had substantially
improved survival. Effective antiviral therapy improves prognosis
[3,4]. Less than 2% of Americans die from liver disease, but more
than one third of veterans with HCV die prematurely from com-
plications of cirrhosis [2,5]. According to a 2010 national VA
report, deaths in veterans with HCV have more than tripled,
‘‘Between 2000 and 2008, the annual number of all cause deaths
recorded for Veterans with chronic HCV rose from 1259 (1129
per 100,000 in VHA care) to 5967 (4049 per 100,000 in VHA care),
respectively’’ [6].
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